Skip to main content

Advertisement

Fig. 5 | Fluids and Barriers of the CNS

Fig. 5

From: Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab

Fig. 5

Distribution of the averaged over all patients’ rCBV voxel values before administration of BEV (pre-BEV, gray), after it using the pre-BEV volume of enhancement (red, ROIpre) and post-BEV volume of enhancement (blue, ROIpost). There is a significant increase in the proportion of hypoperfused voxels (P = 0.008) and a significant decrease in hyperperfused voxels (P = 0.01) in both ROIs after BEV administration

Back to article page